title: Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
authors.forename: John S
authors.initials: JS
authors.lastname: Welch
authors.forename: Jeffery M
authors.initials: JM
authors.lastname: Klco
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Procknow
authors.forename: Geoffery L
authors.initials: GL
authors.lastname: Uy
authors.forename: Keith E
authors.initials: KE
authors.lastname: Stockerl-Goldstein
authors.forename: Camille N
authors.initials: CN
authors.lastname: Abboud
authors.forename: Peter
authors.initials: P
authors.lastname: Westervelt
authors.forename: John F
authors.initials: JF
authors.lastname: DiPersio
authors.forename: Anjum
authors.initials: A
authors.lastname: Hassan
authors.forename: Amanda F
authors.initials: AF
authors.lastname: Cashen
authors.forename: Ravi
authors.initials: R
authors.lastname: Vij
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001853:Bone Marrow / Q000098:blood supply / Q000187:drug effects; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D015331:Cohort Studies; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010087:Oxides / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077209:Decitabine; D001374:Azacitidine; D001205:Ascorbic Acid; D000077237:Arsenic Trioxide